Core Insights - Premier Graphene Inc. and HGI Industrial Technologies are positioned for success in the cannabis and industrial hemp sectors, highlighted by their participation in an international forum in Mexico City [3][4] - The companies have secured a significant COFEPRIS license, allowing them to import and commercialize cannabinoid products in Mexico, marking a major regulatory achievement [4][6] - Innovations in industrial hemp composites and graphene-enhanced medical applications are being developed, positioning the companies at the forefront of biotechnology and materials science [7][12] Regulatory and Market Opportunities - The relationship with Santa Rosa Green Seeds and the COFEPRIS license provides Premier Graphene with a competitive edge in the cannabinoid market [4][6] - The forum discussed the landscape of federal cannabis legalization in Mexico, with HGI recognized for obtaining the Amparo, enabling compliant operations [8] - The recent executive order by President Donald Trump reclassifying cannabis may enhance research and development opportunities in the medical cannabis sector [9][10] Technological Innovations - Advances in using CBD-doped graphene for targeted drug delivery systems are being explored, which could revolutionize treatment for diseases like cancer [7][12] - The integration of cannabinoids and graphene is seen as a new frontier in bioelectric medicine, focusing on restoring healthy electrical signaling in the body [12] Company Profiles - Premier Graphene Inc. focuses on developing high-performance graphene materials from sustainable sources, aiming to lead in innovation and sustainability across multiple industries [13] - HGI Industrial Technologies specializes in industrial hemp development and cannabinoid imports, positioning itself as a leader in the biotech and defense sectors in Mexico [14]

Core Insights - The event highlighted the collaboration between Premier Graphene Inc. and HGI Industrial Technologies, focusing on the future of cannabis, industrial hemp, and advanced materials science in Mexico [1][2] - Premier Graphene has secured a significant regulatory milestone with an official importing license from COFEPRIS, allowing for the importation and commercialization of cannabinoid products [2][4] - The forum discussed advancements in industrial hemp composites and medical applications, positioning Premier and HGI at the forefront of biotechnology and materials science [3][8] Regulatory Developments - Premier's relationship with Santa Rosa Green Seeds enhances its market position, particularly with the exclusive importing license from COFEPRIS [2][11] - HGI Industrial Technologies has obtained the Amparo, enabling it to legally initiate operations in compliance with Mexican regulations [4][10] - The recent executive order by President Donald Trump reclassifying cannabis may significantly impact the cannabis industry, promoting research and development [5][6] Technological Innovations - Dr. Stuart Titus emphasized the potential of cannabinoids in bioelectric medicine, particularly in cancer treatment through targeted drug delivery systems using CBD-doped graphene [3][7] - The integration of cannabinoids and graphene is seen as a new frontier in bioelectric medicine, enhancing cellular communication and restoring healthy electrical signaling [7][8] Market Positioning - Premier Graphene is committed to addressing the needs of the defense and technology sectors while aiming to fill the global gap in graphene production [8][9] - HGI Industrial Technologies is positioned to become a leading importer and developer of legal cannabinoid products in Mexico, leveraging its expertise in cultivation and regulatory compliance [10][11]

Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG0) ("GHG" or the "Company") announces that it has applied to the British Columbia Securities Commission ("BCSC") for a partial revocation order (the "Partial Revocation Order") in connection with the failure-to-file cease trade order ("FFCTO") issued against the Company on April 15, 2025, for failing to file certain continuous disclosure documents (collectively, the "Documents") wi ...